303 related articles for article (PubMed ID: 12511558)
1. A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3.
Subramanian L; Benson MD; Iñiguez-Lluhí JA
J Biol Chem; 2003 Mar; 278(11):9134-41. PubMed ID: 12511558
[TBL] [Abstract][Full Text] [Related]
2. Repression and coactivation of CCAAT/enhancer-binding protein epsilon by sumoylation and protein inhibitor of activated STATx proteins.
Kim J; Sharma S; Li Y; Cobos E; Palvimo JJ; Williams SC
J Biol Chem; 2005 Apr; 280(13):12246-54. PubMed ID: 15661739
[TBL] [Abstract][Full Text] [Related]
3. Small ubiquitin-like modifier 1 (SUMO-1) modification of the synergy control motif of Ad4 binding protein/steroidogenic factor 1 (Ad4BP/SF-1) regulates synergistic transcription between Ad4BP/SF-1 and Sox9.
Komatsu T; Mizusaki H; Mukai T; Ogawa H; Baba D; Shirakawa M; Hatakeyama S; Nakayama KI; Yamamoto H; Kikuchi A; Morohashi K
Mol Endocrinol; 2004 Oct; 18(10):2451-62. PubMed ID: 15192080
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new small ubiquitin-like modifier (SUMO)-interacting motif in the E3 ligase PIASy.
Kaur K; Park H; Pandey N; Azuma Y; De Guzman RN
J Biol Chem; 2017 Jun; 292(24):10230-10238. PubMed ID: 28455449
[TBL] [Abstract][Full Text] [Related]
5. In vitro modification of human centromere protein CENP-C fragments by small ubiquitin-like modifier (SUMO) protein: definitive identification of the modification sites by tandem mass spectrometry analysis of the isopeptides.
Chung TL; Hsiao HH; Yeh YY; Shia HL; Chen YL; Liang PH; Wang AH; Khoo KH; Shoei-Lung Li S
J Biol Chem; 2004 Sep; 279(38):39653-62. PubMed ID: 15272016
[TBL] [Abstract][Full Text] [Related]
6. Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.
Tatham MH; Kim S; Yu B; Jaffray E; Song J; Zheng J; Rodriguez MS; Hay RT; Chen Y
Biochemistry; 2003 Aug; 42(33):9959-69. PubMed ID: 12924945
[TBL] [Abstract][Full Text] [Related]
7. Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation.
Mascle XH; Lussier-Price M; Cappadocia L; Estephan P; Raiola L; Omichinski JG; Aubry M
J Biol Chem; 2013 Dec; 288(51):36312-27. PubMed ID: 24174529
[TBL] [Abstract][Full Text] [Related]
8. Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner.
Dahle Ø; Andersen TØ; Nordgård O; Matre V; Del Sal G; Gabrielsen OS
Eur J Biochem; 2003 Mar; 270(6):1338-48. PubMed ID: 12631292
[TBL] [Abstract][Full Text] [Related]
9. SUMO modification of STAT1 and its role in PIAS-mediated inhibition of gene activation.
Rogers RS; Horvath CM; Matunis MJ
J Biol Chem; 2003 Aug; 278(32):30091-7. PubMed ID: 12764129
[TBL] [Abstract][Full Text] [Related]
10. Sumoylation of CCAAT/enhancer-binding protein alpha and its functional roles in hepatocyte differentiation.
Sato Y; Miyake K; Kaneoka H; Iijima S
J Biol Chem; 2006 Aug; 281(31):21629-21639. PubMed ID: 16735515
[TBL] [Abstract][Full Text] [Related]
11. Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy.
Holmstrom S; Van Antwerp ME; Iñiguez-Lluhi JA
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15758-63. PubMed ID: 14663148
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification.
Ohshima T; Koga H; Shimotohno K
J Biol Chem; 2004 Jul; 279(28):29551-7. PubMed ID: 15123625
[TBL] [Abstract][Full Text] [Related]
13. Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling.
Lee PS; Chang C; Liu D; Derynck R
J Biol Chem; 2003 Jul; 278(30):27853-63. PubMed ID: 12740389
[TBL] [Abstract][Full Text] [Related]
14. Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.
Danciu TE; Chupreta S; Cruz O; Fox JE; Whitman M; Iñiguez-Lluhí JA
J Biol Chem; 2012 May; 287(22):18318-29. PubMed ID: 22493429
[TBL] [Abstract][Full Text] [Related]
15. Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor.
Tirard M; Almeida OF; Hutzler P; Melchior F; Michaelidis TM
Mol Cell Endocrinol; 2007 Mar; 268(1-2):20-9. PubMed ID: 17314004
[TBL] [Abstract][Full Text] [Related]
16. Post-translational modification of Rta of Epstein-Barr virus by SUMO-1.
Chang LK; Lee YH; Cheng TS; Hong YR; Lu PJ; Wang JJ; Wang WH; Kuo CW; Li SS; Liu ST
J Biol Chem; 2004 Sep; 279(37):38803-12. PubMed ID: 15229220
[TBL] [Abstract][Full Text] [Related]
17. SUMO: getting it on.
Anckar J; Sistonen L
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1409-13. PubMed ID: 18031233
[TBL] [Abstract][Full Text] [Related]
18. Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription.
Spengler ML; Brattain MG
J Biol Chem; 2006 Mar; 281(9):5567-74. PubMed ID: 16407261
[TBL] [Abstract][Full Text] [Related]
19. SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.
Holmstrom SR; Chupreta S; So AY; Iñiguez-Lluhí JA
Mol Endocrinol; 2008 Sep; 22(9):2061-75. PubMed ID: 18562626
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1.
Bernier-Villamor V; Sampson DA; Matunis MJ; Lima CD
Cell; 2002 Feb; 108(3):345-56. PubMed ID: 11853669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
